

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3978727

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
POLYMER TECHNOLOGY SYSTEMS, INC.	12/16/2011

**RECEIVING PARTY DATA**

<b>Name:</b>	PNC BANK, NATIONAL ASSOCIATION, AS AGENT
<b>Street Address:</b>	500 FIRST AVENUE
<b>Internal Address:</b>	COMMERCIAL LOAN SERVICE/DCC
<b>City:</b>	PITTSBURGH
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	15219

**PROPERTY NUMBERS Total: 49**

Property Type	Number
Application Number:	15004553
PCT Number:	US1614562
Application Number:	14952360
PCT Number:	US1562706
Application Number:	14952015
PCT Number:	US1562703
Application Number:	62296467
Application Number:	62271220
Application Number:	62271226
Application Number:	62271228
Application Number:	62234528
Application Number:	62337557
Application Number:	62268962
Application Number:	62271759
Application Number:	15093236
PCT Number:	US1626430
Application Number:	15061845
PCT Number:	US1621040
Application Number:	62212991

PATENT

Property Type	Number
Application Number:	62317259
Application Number:	62213469
Application Number:	15167533
PCT Number:	US1634786
Application Number:	62268959
Application Number:	62271753
Application Number:	15134156
PCT Number:	US1628469
Application Number:	62271229
Application Number:	62322093
Application Number:	62268956
Application Number:	15004570
PCT Number:	US1614568
Application Number:	62263478
Application Number:	62146080
Application Number:	14961634
Application Number:	62234525
Application Number:	62234527
Application Number:	62268971
Application Number:	62271223
Application Number:	62212994
Application Number:	62322089
Application Number:	15012348
PCT Number:	US1615956
Application Number:	62342079
Application Number:	62268967
Application Number:	15004589
PCT Number:	US1614575
Application Number:	62316323
Application Number:	62322687

**CORRESPONDENCE DATA**

Fax Number: (216)363-4588

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 216.363.4677

Email: patent@beneschlaw.com

Correspondent Name: DUNCAN H. POIRIER

Address Line 1: BENESCH FRIEDLANDER COPLAN & ARONOFF LLP

Address Line 2: 200 PUBLIC SQUARE, SUITE 2300

**PATENT**

**REEL: 039472 FRAME: 0763**

**Address Line 4:** CLEVELAND, OHIO 44114

**ATTORNEY DOCKET NUMBER:** 34949-2

**NAME OF SUBMITTER:** DUNCAN H. POIRIER

**SIGNATURE:** /Duncan H. Poirier/

**DATE SIGNED:** 07/26/2016

**Total Attachments: 40**

source=IPSA#page1.tif  
source=IPSA#page2.tif  
source=IPSA#page3.tif  
source=IPSA#page4.tif  
source=IPSA#page5.tif  
source=IPSA#page6.tif  
source=IPSA#page7.tif  
source=IPSA#page8.tif  
source=IPSA#page9.tif  
source=IPSA#page10.tif  
source=IPSA#page11.tif  
source=IPSA#page12.tif  
source=IPSA#page13.tif  
source=IPSA#page14.tif  
source=IPSA#page15.tif  
source=IPSA#page16.tif  
source=IPSA#page17.tif  
source=IPSA#page18.tif  
source=IPSA#page19.tif  
source=IPSA#page20.tif  
source=IPSA#page21.tif  
source=IPSA#page22.tif  
source=IPSA#page23.tif  
source=IPSA#page24.tif  
source=IPSA#page25.tif  
source=IPSA#page26.tif  
source=IPSA#page27.tif  
source=IPSA#page28.tif  
source=IPSA#page29.tif  
source=IPSA#page30.tif  
source=IPSA#page31.tif  
source=IPSA#page32.tif  
source=IPSA#page33.tif  
source=IPSA#page34.tif  
source=IPSA#page35.tif  
source=IPSA#page36.tif  
source=IPSA#page37.tif  
source=IPSA#page38.tif  
source=IPSA#page39.tif  
source=IPSA#page40.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement, as it may be amended, restated or otherwise modified from time to time (this "Agreement"), is executed and delivered as of this 16<sup>th</sup> day of December 2011, by POLYMER TECHNOLOGY SYSTEMS, INC., a corporation organized under the laws of the State of Indiana (together with its successors and assigns, "Pledgor"), to PNC BANK, NATIONAL ASSOCIATION (together with its successors and assigns in its capacity as agent, "Agent"), as agent for the financial institutions which are now or which hereafter become a party to the Credit Agreements, as hereinafter defined (collectively, "Lenders").

### RECITALS:

Pledgor, certain other Credit Parties which from time to time become party thereto, Agent and Lenders are entering into that certain Revolving Credit, Term Loan, Guaranty and Security Agreement, dated as of the date hereof (as the same may from time to time be amended, restated or otherwise modified, the "Domestic Credit Agreement") and that certain Export Revolving Credit, Guaranty and Security Agreement (the "Export Credit Agreement" and together with the Domestic Credit Agreement, collectively, the "Credit Agreements"). Pledgor desires that Lenders grant to Pledgor the financial accommodations as described in the Credit Agreements.

Pledgor deems it to be in its direct pecuniary and business interests that Pledgor obtain from Lenders the Advances (as defined in the Credit Agreements), and other financial accommodations provided for in the Credit Agreements.

Pledgor understands that Agent and Lenders are willing to enter into the Credit Agreements and to grant to Pledgor the Advances and such financial accommodations only upon certain terms and conditions, one of which is that Pledgor grant to Agent, for the benefit of Lenders, a security interest in, and an assignment of, the Collateral, as hereinafter defined, and this Agreement is being executed and delivered in consideration of Agent and Lenders entering into the Credit Agreements, granting to Pledgor the Advances and such other financial accommodations and for other valuable consideration.

NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Definitions. As used herein, the following terms shall have the following meanings:

"Assignment" shall mean an Assignment in the form of Exhibit A hereto.

"Collateral" shall mean, collectively, all of Pledgor's existing and future (a) Patents; (b) Trademarks; (c) Licenses; (d) all of the goodwill of Pledgor's business, including, but not limited to, all goodwill connected with and symbolized by the Trademarks; and (e) proceeds of any of the foregoing.

"Debt" shall mean the Obligations, as such term is defined in the Credit Agreements.

"Licenses" shall mean any license agreement with any other party, whether Pledgor is a licensor or licensee under any such license agreement, if any, including, without limitation, the licenses listed on Schedule C attached hereto and made a part hereof, and the right to prepare for sale, sell and advertise for sale, all Inventory now or hereafter owned by Pledgor and now or hereafter covered by such licenses.

"Patents" shall mean any patent and patent application, including, without limitation, the inventions and improvements described and claimed therein, if any, and those patents listed on Schedule A attached hereto and made a part hereof, and (a) the reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof; (b) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, damages and payments for past or future infringements thereof; (c) the right to sue for past, present and future infringements thereof; and (d) all rights corresponding thereto throughout the world.

"Obligor" shall mean a Person whose credit or any of whose property is pledged to the payment of any portion of the Debt and includes, without limitation, (a) Pledgor, (b) any Guarantor and (c) any signatory to an Other Document.

"PTO" shall mean the United States Patent and Trademark Office.

"Trademarks" shall mean any registered trademark, trademark registration, trade name and trademark application, registered service mark, service mark registration, service name and service mark application, if any, including, without limitation, the trademarks, trademark registrations, trade names and trademark applications, service marks, service mark registrations, service names and service mark applications listed on Schedule B attached hereto and made a part hereof, and (a) renewals thereof; (b) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, damages and payment for past or future infringements thereof; (c) the right to sue for past, present and future infringements thereof; and (d) all rights corresponding thereto throughout the world.

Capitalized terms used in this Agreement without definition have the meanings ascribed to such terms in the Credit Agreements.

2. Grant of Security Interest. In consideration of and as security for the full and complete payment of all of the Debt, Pledgor hereby agrees that Agent shall at all times have, and hereby grants to Agent, for its benefit and for the ratable benefit of each Lender, a security interest in all of the Collateral, including (without limitation) all of Pledgor's future Collateral, irrespective of any lack of knowledge by Agent or Lenders of the creation or acquisition thereof.

3. Warranties and Representations. Pledgor represents and warrants to Agent and Lenders that as of the date hereof:

(a) Pledgor owns all of the Collateral and, whether the same are registered or unregistered, no such Collateral has been adjudged invalid or unenforceable;

(b) except as set forth in Schedules 5.9 and 5.10 of the Credit Agreements, Pledgor has no knowledge of any claim that the use of any of the Collateral does or may violate the rights of any Person;

(c) except for Permitted Encumbrances and for licenses granted by Pledgor as licensor listed on Schedule 5.9 of the Credit Agreements, Pledgor is the sole and exclusive owner of the entire and unencumbered right, title and interest in and to the Collateral, free and clear of any liens, charges and encumbrances, including, without limitation, pledges, assignments, licenses, registered user agreements and covenants by Pledgor not to sue third Persons;

(d) Pledgor has full power, authority and legal right to pledge the Collateral and enter into this Agreement and perform its terms;

(e) Pledgor has used, and shall continue to use, for the duration of this Agreement, proper statutory notice in connection with its use of the Collateral;

(f) Pledgor represents and warrants that it is the true and lawful owner or licensee of the Trademarks listed on Schedule B and Schedule C attached hereto and made a part hereof, and that said listed Trademarks constitute all the marks registered in the PTO that such Pledgor now owns or uses in connection with its business, other than any such marks which are (i) owned but not used and (ii) not material to its business. Pledgor represents and warrants that it owns or is licensed to use all Trademarks that it uses, and that it owns all of the registrations listed on Schedule B. Pledgor further warrants that it is not aware of any third party claim that any aspect of Pledgor's present or contemplated business operations infringes or will infringe on any registered trademark or registered service mark; and

(g) Pledgor represents and warrants that it is the true and lawful owner or licensee of all rights in the Patents listed on Schedule A and Schedule C attached hereto and made a part hereof, that said Patents constitute all the United States patents and applications for United States patents that Pledgor now owns, other than any such patents, applications and registrations which are (i) owned but not used and (ii) not material to its business. Pledgor represents and warrants that it owns or is licensed to use or practice under all Patent registrations and applications that it owns, uses or practices under, and that it owns all of the Patent registrations and applications listed on Schedule A. Pledgor further warrants that it is not aware of any third party claim that any aspect of Pledgor's present or contemplated business operations infringes or will infringe on any patent except as may be disclosed in Schedule 5.8(b) of the Credit Agreements.

4. Further Assignment Prohibited. Pledgor shall not enter into any agreement that is inconsistent with Pledgor's obligations under this Agreement and shall not otherwise sell or assign its interest in, or grant any license or sublicense with respect to, any of the Collateral other than as permitted under Section 4.3 of the Credit Agreements or with Agent's prior written consent. Absent permission under such Section 4.3 or such prior written consent, any such attempted sale or license is null and void.

5. Right to Inspect. Pledgor hereby grants to Agent and Lenders and their respective employees and agents the right to visit any location of Pledgor and to inspect Pledgor's books and records and to make excerpts therefrom and transcripts thereof at such times and upon such notice as is set forth in the Credit Agreements.

6. Standard Patent and Trademark Use. Pledgor shall not knowingly use the Collateral in any manner that would jeopardize the validity or legal status thereof. Pledgor shall comply with all patent marking requirements as specified in 35 U.S.C. §287. Pledgor shall further conform its usage of any trademarks to standard trademark usage, including, but not limited to, using the trademark symbols ®, ™, and ™ where appropriate.

7. Event of Default.

(a) Pledgor expressly acknowledges that Agent may record this Agreement with the PTO. Contemporaneously herewith, Pledgor shall also execute and deliver to Agent the Assignment, which Assignment shall have no force and effect and shall be held by Agent, in escrow, until the occurrence of an Event of Default; provided that, anything herein to the contrary notwithstanding, the security interest granted herein shall be effective as of the date of this Agreement. After the occurrence of an Event of Default which is not cured within any applicable cure period or waived, the Assignment shall take effect immediately upon certification of such fact by an authorized officer of Agent in the form attached as Exhibit A and upon written notice to Pledgor and thereafter Agent may, in its sole discretion, record the Assignment with the PTO. The provisions of this paragraph (a) shall not limit or contradict the provisions of the following paragraph (b) or any of the rights and remedies of Agent described therein.

(b) If an Event of Default shall occur and be continuing, in addition to Agent's rights to elect to make the Assignment effective as provided for in paragraph (a) above, Pledgor irrevocably authorizes and empowers Agent, on behalf of Lenders, to terminate Pledgor's use of the Collateral and to exercise such rights and remedies as allowed by law, including without limitation all rights and remedies of a secured party under the UCC. Without limiting the generality of the foregoing, Agent may sell at public or private sale, in a commercially reasonable manner, or otherwise realize upon all or, from time to time, any of the Collateral, together with the associated goodwill, or any interest that Pledgor may have therein, and, after deducting from the proceeds of sale or other disposition of the Collateral all reasonable expenses (including all expenses for attorneys' and brokers' fees and other legal services), Agent shall apply such proceeds against payment of the Debt in accordance with the terms of the Credit Agreements. Notice of any sale or other disposition of the Collateral shall be given to Pledgor at least ten (10) days before the time of any intended public or private sale or other disposition of the Collateral is to be made, which Pledgor hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition, Agent or any Lender may, to the extent permissible under applicable law, purchase the whole or any part of the Collateral sold, free from any right of redemption on the part of Pledgor, which right is hereby waived and released.

8. Termination. At such time as the Debt has been irrevocably paid in full, the commitments of Lenders under the Credit Agreements terminated, and the Credit Agreements terminated and not replaced by any other credit facility with Agent and Lenders (or any of them), this Agreement shall terminate and Agent shall, upon Pledgor's request, execute and deliver to Pledgor, at Pledgor's expense, all deeds, assignments, and other instruments as Pledgor shall reasonably request to evidence the release of Agent's security interest in the Collateral in connection with such termination, subject to any disposition thereof that may have been made by Agent pursuant hereto; provided, however that the provisions of Sections 9, 11, 22, 23, 24, 26 and 28 shall survive any termination of this Agreement.

9. Maintaining Collateral, Attorneys' Fees, Costs and Expenses. Pledgor shall have the obligation and duty to perform all acts reasonably necessary to maintain or preserve the Collateral. Any and all fees, costs and expenses, of whatever kind or nature, including, without limitation, the reasonable attorneys' fees and legal expenses incurred by Agent and Lenders in connection with the amendment and enforcement of this Agreement, all renewals, required affidavits and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, reasonable counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining or preserving the Collateral, or in defending or prosecuting any actions or proceedings arising out of or related to the Collateral, shall be borne and paid by Pledgor, within ten (10) days of demand by Agent, and, until so paid after demand, shall be added to the principal amount of the Debt and secured by the Collateral (and all other "Collateral" as defined in the Credit Agreements).

10. Pledgor's Obligations to Prosecute. Except as otherwise agreed to by Agent in writing or to the extent not material to its business, Pledgor shall have the duty to prosecute diligently any patent application or trademark application pending as of the date of this Agreement or thereafter until the Debt shall have been paid in full, and to do any and all acts that are reasonably necessary or desirable to preserve and maintain all rights in the Collateral, including, but not limited to, payment of any maintenance fees. Any expenses incurred by Agent in connection with the Collateral shall be borne by Pledgor. Pledgor shall not abandon any Collateral having an aggregate value of more than \$50,000 without the prior written consent of Agent.

11. Agent's Rights to Enforce. Pledgor shall have the right but not the obligation to bring any opposition proceedings, cancellation proceedings or lawsuit in its own name to enforce or protect the Collateral. Agent and Lenders shall have the right, but shall have no obligation, to join in any such action during the existence of an Event of Default. Pledgor shall promptly, and in any event within ten (10) days of demand, reimburse and indemnify Agent and Lenders for all damages, and expenses, including reasonable attorneys' fees incurred by Agent in connection with the provisions of this Section 11, in the event Agent and Lenders elect to join in any such action commenced by Pledgor.

12. Power of Attorney. Pledgor hereby authorizes and empowers Agent, on behalf of Lenders, to make, constitute and appoint any officer or agent of Agent as Agent may select, in its exclusive discretion, as Pledgor's true and lawful attorney-in-fact, after the occurrence and during the continuance of an Event of Default, with the power to endorse Pledgor's name on all applications, documents, papers and instruments reasonably necessary for Agent to use the Collateral, or to grant or issue any exclusive or nonexclusive license under the Collateral to any third party, or reasonably necessary for Agent to assign, pledge, convey or otherwise transfer title in or dispose of the Collateral, together with associated goodwill to a third party or parties, including the power to execute in the name of Pledgor and deliver to the PTO for recording instruments of assignment and/or transfer for all or any part of the Collateral naming as assignee or transferee either Agent or any party that may purchase all or any part of the Collateral at any public or private sale conducted by Agent as a secured creditor. Pledgor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney shall be irrevocable for the life of this Agreement.

13. Agent's Right to Perform Obligations. If Pledgor materially fails to comply with any of its obligations under this Agreement, Agent, on behalf of Lenders, may after notice to



Pledgor, but is not obligated to, do so in Pledgor's name or in Agent's name, but at Pledgor's expense, and Pledgor hereby agrees to reimburse Agent on demand in full for all expenses, including reasonable attorneys' fees, incurred by Agent in protecting, defending and maintaining the Collateral.

14. Additional Documents. Pledgor shall, upon written request of Agent, enter into such additional documents or instruments as may be reasonably required by Agent in order to effectuate, evidence or perfect Agent's interests in the Collateral as evidenced by this Agreement.

15. New Collateral. If, before the Debt shall have been satisfied in full, Pledgor shall obtain rights to any new Collateral, the provisions of Sections 2 and 7 hereof shall automatically apply thereto as if the same were identified on Schedules A, B or C attached hereto and made a part hereof as of the date hereof, and Pledgor shall give Agent prompt written notice thereof as required in the Credit Agreements.

16. Modification for New Collateral. Pledgor hereby authorizes Agent to modify this Agreement by amending Schedules A, B and/or C to include any future Collateral as contemplated by Sections 2 and 15 hereof and, at Agent's request, Pledgor shall execute any documents or instruments reasonably required by Agent in order to modify this Agreement as provided in this Section 16, provided that any such modification to Schedules A, B and/or C shall be effective without the signature of Pledgor. Pledgor hereby acknowledges that Agent may refile or re-record this Agreement with the PTO, together with any such modification to Schedules A, B and/or C.

17. No Waiver. No course of dealing between Pledgor and Agent and Lenders, nor any failure to exercise, nor any delay in exercising, on the part of Agent or Lenders, any right, power or privilege hereunder or under any of the Other Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

18. Remedies Cumulative. All of the rights and remedies of Agent and Lenders with respect to the Collateral, whether established hereby or by the Other Documents, or by any other agreements or by law shall be cumulative and may be executed singularly or concurrently.

19. Severability. The provisions of this Agreement are severable, and, if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision of this Agreement in any jurisdiction.

20. Modifications. Except as provided in Section 16 hereof, this Agreement may be amended or modified only by a writing signed by Pledgor and Agent, on behalf of Lenders. In the event that any provision herein is deemed to be inconsistent with any provision of any other document, other than the Credit Agreements, the provisions of this Agreement shall control.

21. Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties, except that Pledgor may not assign any of its rights or duties hereunder without the prior written consent of Agent.

Any attempted assignment or transfer without the prior written consent of Agent shall be null and void.

22. Notice. All notices, requests, demands and other communications provided for hereunder shall be given to or made upon Pledgor or Agent as the case may be, in accordance with the terms of Section 17.6 of the Credit Agreements.

23. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Ohio applied to contracts to be performed wholly within the State of Ohio. Any judicial proceeding brought by or against Pledgor with respect to this Agreement or any related agreement may be brought in any court of competent jurisdiction in the State of Ohio, United States of America, and by execution and delivery of this Agreement, Pledgor accepts for itself and in connection with its properties, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts, and irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Pledgor hereby waives personal service of any and all process upon it and consents that all such service of process may be made by registered mail (return receipt requested) directed to Pledgor at its address set forth in Section 17.6 of the Credit Agreements and service so made shall be deemed completed five (5) Business Days after the same shall have been so deposited in the mails of the United States of America, or, at the Agent's option, by service upon Borrowing Agent which Pledgor irrevocably appoints as Pledgor's agent for the purpose of accepting service within the State of Ohio. Nothing herein shall affect the right to serve process in any manner permitted by law or shall limit the right of Agent or any Lender to bring proceedings against Pledgor in the courts of any other jurisdiction. Pledgor waives any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. Pledgor waives the right to remove any judicial proceeding brought against Pledgor in any state court to any federal court. Notwithstanding anything to the contrary contained in the foregoing, any judicial proceeding by Pledgor against Agent or any Lender involving, directly or indirectly, any matter or claim in any way arising out of, related to or connected with this Agreement or any related agreement, shall be brought only in a federal or state court located in the County of Cuyahoga, State of Ohio.

24. Indemnity: Administration and Enforcement. Pledgor will reimburse each Lender, on that Lender's demand from time to time, and Agent, on Agent's demand from time to time, for any and all reasonable fees, costs, and reasonable expenses (including, without limitation, the reasonable fees and disbursements of legal counsel) reasonably incurred by that Lender or Agent, as the case may be, in administering this Agreement and in protecting, enforcing, or attempting to protect or enforce its rights under this Agreement, together with interest thereon, following notice received by Pledgor, at a rate per annum equal to the Default Rate.

25. Unconditional and Continuing Security Interest. Pledgor's obligations under this Agreement and the granting of a security interest to Agent pursuant to this Agreement are unconditional and effective immediately, and (except for obligations surviving indefinitely pursuant to Section 8) those obligations and the security interest so granted shall continue in full effect until the Debt shall have been paid in full, regardless of the lapse of time, regardless of the fact that there may be a time or times when no Debt is outstanding, regardless of any act, omission, or course of dealing whatever on the part of Agent and Lenders, or any of them, and regardless of any other event, condition, or thing. Without limiting the generality of the foregoing, neither the amount of the Debt for purposes of this Agreement, nor Pledgor's

obligations under this Agreement, nor the security interest granted pursuant to this Agreement shall be diminished or impaired by:

(a) the granting by Agent or any Lender of any credit to any Obligor, whether or not liability therefor constitutes Debt, or any failure or refusal of Agent or any Lender to grant any other credit to any Obligor even if Agent or such Lender thereby breaches any duty or commitment to Pledgor or any other Person,

(b) the application by Agent or any Lender of credits, payments, or proceeds to any portion of the Debt,

(c) any extension, renewal, or refinancing of the Debt in whole or in part,

(d) any amendment, restatement, or other modification of any kind in, to, or of the Credit Agreements or any Other Document, or any consent or other indulgence granted to any Obligor, or any waiver of any Event of Default (under this Agreement or the Credit Agreements), including without limitation, (i) any extension or change in the time of payment, and/or the manner, place or terms of payment of any or all of Debt, (ii) any renewal, extension of the maturity of the Debt, (iii) any increase or decrease of any loans and extension of credit (and/or any maximum credit limits or sublimits with respect to any such loans or extensions of credit) constituting the Debt, and/or making available to Pledgor or other Credit Parties any new or additional or increased loans or extensions of credit (whether such new, additional or increased loans or extensions of credit are the same or of new or different types as the loans and extensions of credit available to Pledgor and the other Credit Parties under the Credit Agreements and the other Debt as of the date hereof) and (iv) any modification of the terms and conditions under which loans and extensions of credit may be made under the Credit Agreements,

(e) any acceptance of security for or any other Obligor on the Debt or any part thereof, or any release of any security or other Obligor (or compromise or settlement of the liability of any Obligor for the Debt), whether or not Agent or any Lender receives consideration for the release, compromise or settlement,

(f) any discharge of the Debt in whole or in part under any bankruptcy or insolvency law or otherwise,

(g) the failure of Agent or any Lender to make any presentment or demand for payment, to assert or perfect any claim, demand, Lien or interest, or to enforce any right or remedy, or any delay or neglect by Agent or any Lender in respect of the Debt or any part thereof or any security therefor,

(h) any failure to give Pledgor notice of (i) the making of any loan or other credit extension or the terms, conditions, and other provisions applicable thereto, (ii) any dishonor by Pledgor or any other Obligor, or (iii) the inaccuracy or incompleteness of any representation, warranty, or other statement made by any Obligor, or

(i) any defense that may now or hereafter be available to any Obligor, whether based on suretyship, impairment of collateral, accord and satisfaction, breach of warranty, breach of contract, failure of consideration, tort, lack of capacity, usury, or otherwise, or any illegality, invalidity, or unenforceability of the Debt or any part thereof or of any Other Document.

26. No Setoff, Rights Against Other Obligors. Pledgor hereby (a) waives all now existing or hereafter arising rights to recoup or offset any obligation of Pledgor under this Agreement against any claim or right of Pledgor against Agent or any Lender, (b) waives all rights of exoneration now or hereafter arising out of or in connection with this Agreement, and (c) agrees that unless and until all of the Debt shall have been paid in full, Pledgor will not assert against any other Obligor or any other Obligor's property any rights (including, without limitation, contribution, indemnification, reimbursement, and subrogation) now or hereafter arising (whether by contract, operation of law, or otherwise) out of or in connection with this Agreement.

27. Credit Support Document. The parties hereto acknowledge that this Agreement is intended to act (i) as a "Credit Support Document" (as defined in the 1994 ISDA Definitions) with respect to each party and is made part of the to the ISDA Master Agreement, executed in connection herewith (such ISDA Master Agreement, together with each schedule attached thereto and each confirmation delivered in connection therewith, as amended, modified or supplemented from time to time, herein referred to as the "Master Agreement") and the Schedule to the ISDA Master Agreement executed in connection herewith, each by and between the Borrowers and Agent, which Master Agreement includes all Schedules thereto and all Confirmation exchanged between the parties confirming the transactions thereunder, and (ii) as a "transfer" under a swap agreement within the meaning of the U.S. Bankruptcy Code Section 546(g). The parties hereto hereby acknowledge and agree that the Liens granted by the Pledgor to the Secured Party for the benefit of the Secured Party and the Lenders hereunder also secure the payment of each Lender-Provided Interest Rate Hedge and that such Liens secure the Lender-Provided Interest Rate Hedges and rank *pari passu* with the Liens hereof to secure the other Obligations.

[The remainder of this page intentionally left blank]

27. JURY TRIAL WAIVER. EACH PARTY TO THIS AGREEMENT, TO THE EXTENT PERMITTED BY LAW, WAIVES ANY RIGHT TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE, AMONG AGENT, LENDERS AND PLEDGOR, OR ANY OF THEM, ARISING OUT OF, IN CONNECTION WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS AGREEMENT OR ANY NOTE OR OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH OR THE TRANSACTIONS RELATED THERETO AND EACH PARTY HEREBY CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENTS OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. THIS WAIVER SHALL NOT IN ANY WAY AFFECT, WAIVE, LIMIT, AMEND OR MODIFY THE ABILITY OF AGENT OR ANY LENDER TO PURSUE REMEDIES PURSUANT TO ANY PROVISION CONTAINED IN ANY NOTE, OR OTHER INSTRUMENT, DOCUMENT OR AGREEMENT AMONG PLEDGOR, AGENT AND LENDERS, OR ANY OF THEM.

POLYMER TECHNOLOGY SYSTEMS, INC.

By: 

Print Name: Robert S. Huffstadt

Title: President and CEO

PNC BANK, NATIONAL ASSOCIATION,  
as Agent and as a Lender

By: \_\_\_\_\_

Print Name: \_\_\_\_\_

Title: \_\_\_\_\_

[Signature Page – IP Security Agreement – PTS]


**PATENT**  
**REEL: 039472 FRAME: 0774**

27. JURY TRIAL WAIVER. EACH PARTY TO THIS AGREEMENT, TO THE EXTENT PERMITTED BY LAW, WAIVES ANY RIGHT TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE, AMONG AGENT, LENDERS AND PLEDGOR, OR ANY OF THEM, ARISING OUT OF, IN CONNECTION WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS AGREEMENT OR ANY NOTE OR OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH OR THE TRANSACTIONS RELATED THERETO AND EACH PARTY HEREBY CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENTS OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. THIS WAIVER SHALL NOT IN ANY WAY AFFECT, WAIVE, LIMIT, AMEND OR MODIFY THE ABILITY OF AGENT OR ANY LENDER TO PURSUE REMEDIES PURSUANT TO ANY PROVISION CONTAINED IN ANY NOTE, OR OTHER INSTRUMENT, DOCUMENT OR AGREEMENT AMONG PLEDGOR, AGENT AND LENDERS, OR ANY OF THEM.

POLYMER TECHNOLOGY SYSTEMS, INC.

By: \_\_\_\_\_  
Print Name: \_\_\_\_\_  
Title: \_\_\_\_\_

PNC BANK, NATIONAL ASSOCIATION,  
as Agent and as a Lender

By:  \_\_\_\_\_  
Print Name: J. Denforth  
Title: V.P.

[Signature Page - IP Security Agreement - PTS]

SCHEDULE A

Patents

See attached.

Patent Report By Invention  
Search Criteria

Client ID 53478

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

**A1C Enzymatic Variant Correction**

UNITED STATES	53478.00166PV01	NEW					PROPOSED
---------------	-----------------	-----	--	--	--	--	----------

**A1C Stability Formulations**

UNITED STATES	53478.00169PV01	NEW					PROPOSED
---------------	-----------------	-----	--	--	--	--	----------

**Algorithm For A1C Variants Elimination Using Four-Strip Detection Methods**

UNITED STATES	53478.00158PV01	NEW					PROPOSED
---------------	-----------------	-----	--	--	--	--	----------

**Anabasine Derivatives For Bio-Conjunction Antigen Preparation And Assay Development**

UNITED STATES	53478.00155PV01	NEW	1/22/2015	62/106623			INACTIVE
UNITED STATES	53478.00155US01	FCA	1/22/2016	15/004668			INACTIVE
WIPO	53478.00155WO01	CEQ	1/22/2016	PCT/US2016/014585			INACTIVE

**Anabasine Test Strip**

UNITED STATES	53478.00146PV01	NEW	1/22/2015	62/106611			PENDING
UNITED STATES	53478.00146US01	FCA	1/22/2016	15/004553			PENDING
WIPO	53478.00146WO01	CEQ	1/22/2016	PCT/US2016/014562			PENDING

**Analyte Monitor**

BRAZIL	53478.00023BR01	DCA	12/28/2012	BR112014016019-8			PENDING
CANADA	53478.00023CA01	DCA	12/28/2012	2862447			PENDING
CHINA	53478.00023CN01	DCA	12/28/2012	201280065002.8			PUBLISHED
EUROPEAN PATENT CON	53478.00023EP01	DCA	12/28/2012	12815975.3			PUBLISHED
INDIA	53478.00023IN01	DCA	12/28/2012	5271/CHENP/2014			PENDING
JAPAN	53478.00023JP01	DCA	12/28/2012	2014-550507			PUBLISHED
MEXICO	53478.00023MX01	DCA	12/28/2012	MX/aj/2014/007953			PUBLISHED
PHILIPPINES	53478.00023PH01	DCA	12/28/2012	PH1-2014-501437			PENDING
RUSSIA	53478.00023RU01	DCA	12/28/2012	2014131256			PUBLISHED
WIPO	53478.00023WO01	CEQ	12/28/2012	PCT/US2012/072054			INACTIVE

**Analyte Monitor**

UNITED STATES	53478.00023US01	FCA	12/28/2012	13/729919			PUBLISHED
---------------	-----------------	-----	------------	-----------	--	--	-----------



COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

### Analytical Systems, Devices, And Cartridges Therefor

UNITED STATES	53478.00021US01	NEW	5/5/2004	10/840344	2/15/2011	7887750	ISSUED
CANADA	53478.00021CA01	DCA	5/4/2005	2565732	3/24/2015	2565732	ISSUED
CHINA	53478.00021CN01	DCA	5/4/2005	200580018683.2	9/14/2011	1964789	ISSUED
HONG KONG	53478.00021HK01	CEQ	5/4/2005	20070112373	12/16/2011	1103677	ISSUED
INDIA	53478.00021IN01	DCA	5/4/2005	4472/CHENP/2006	12/9/2013	258142	ISSUED
JAPAN	53478.00021JP01	DIV	5/4/2005	2012-223058	7/3/2015	5771173	ISSUED
JAPAN	53478.00021JP02	DCA	5/4/2005	2007511610	12/7/2012	5148270	ISSUED
NORWAY	53478.00021NO01	DCA	5/4/2005	200605334			PUBLISHED
WIPO	53478.00021WO01	CEQ	5/4/2005	PCT/US2005/0157 54			INACTIVE
UNITED STATES	53478.00021US02	DIV	12/14/2010	12/967908	10/21/2014	8865089	ISSUED

### Apparatus And Method Of Manufacturing Bodily Fluid Test Strip

UNITED STATES	53478.00011US01	DIV	5/3/2010	12/772707	11/13/2012	8307531	ISSUED
---------------	-----------------	-----	----------	-----------	------------	---------	--------

### Apparatus And Methods For Determining Substances Contained In A Body Fluid

GERMANY	53478.00008DE01	DCA	10/20/1995	95938118.7	8/18/1999	0750739	INACTIVE
EUROPEAN PATENT CON	53478.00008EP01	DCA	10/20/1995	95938118.7	8/18/1999	0750739	EXPIRED
FRANCE	53478.00008FR01	DCA	10/20/1995	95938118.7	8/18/1999	0750739	INACTIVE
ITALY	53478.00008IT01	DCA	10/20/1995	95938118.7	8/18/1999	0750739	INACTIVE

### Blood Separation System And Method For A Dry Test Strip

BRAZIL	53478.00018BR01	DCA	4/23/2012	BR112013021963- 7			PENDING
CHINA	53478.00018CN01	DCA	4/23/2012	201280010517.8			PUBLISHED
GERMANY	53478.00018DE01	DCA	4/23/2012	112012000326.8	4/8/2014	112012000326.8	ISSUED
UNITED KINGDOM	53478.00018GB01	DCA	4/23/2012	GB1317190.5			PUBLISHED
JAPAN	53478.00018JP01	DCA	4/23/2012	2014-506620			PUBLISHED
MEXICO	53478.00018MX01	DCA	4/23/2012	MX/a/2013/011196	12/3/2015	335380	ISSUED
WIPO	53478.00018WO01	NEW	4/23/2012	PCT/US2012/0346 88			INACTIVE
INDIA	53478.00018IN01	DCA	6/26/2013	2078/KOLNP/2013			PENDING

### Blood Separation System And Method For A Dry Test Strip

UNITED STATES	53478.00018US01	FCA	4/23/2012	13/453465			PUBLISHED
---------------	-----------------	-----	-----------	-----------	--	--	-----------

### Body Fluid Guiding Capillary Structure For Self-Contained Test Unit

EUROPEAN PATENT CON	53478.00188EP04	DCA	12/18/2013	13818721.6			PENDING
---------------------	-----------------	-----	------------	------------	--	--	---------

### Body Fluid Sample Test Meter

UNITED STATES	53478.00171US01	NEW	5/2/2006	29/259158	2/12/2008	D561905	ISSUED
---------------	-----------------	-----	----------	-----------	-----------	---------	--------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
<b>Body Fluid Test Apparatus With Detachably Mounted Protoble Tester</b>							
GERMANY	53478.00013DE01	DCA	4/23/2002	02771810.5	8/30/2006	1399059	ISSUED
EUROPEAN PATENT CON	53478.00013EP01	OTH	4/23/2002	02771810.5	8/30/2006	1399059	ISSUED
UNITED KINGDOM	53478.00013GB01	DCA	4/23/2002	02771810.5	8/30/2006	1399059	ISSUED
UNITED STATES	53478.00013US01	FCA	4/24/2002	10/131437	2/1/2005	6849237	ISSUED
<b>Body Fluid Testing Component For Simultaneous Analyte Detection</b>							
UNITED STATES	53478.00188PV01	NEW	4/1/2005	60/667240			INACTIVE
CANADA	53478.00188CA01	DCA	3/30/2006	2601720	8/12/2014	2601720	ISSUED
GERMANY	53478.00188DE01	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
EUROPEAN PATENT CON	53478.00188EP01	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
EUROPEAN PATENT CON	53478.00188EP02	DIV	3/30/2006	15200495.8			PUBLISHED
FRANCE	53478.00188FR01	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
UNITED KINGDOM	53478.00188GB02	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
ITALY	53478.00188IT01	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
POLAND	53478.00188PL01	DCA	3/30/2006	06748840.3	2/3/2016	1866637	ISSUED
UNITED STATES	53478.00188US01	FCA	3/30/2006	11/393439	3/27/2012	8145431	ISSUED
WIPO	53478.00188WO01	CEQ	3/30/2006	PCT/US2006/0113 75			INACTIVE
UNITED STATES	53478.00188US02	CON	3/26/2012	13/506088	1/13/2015	8935007	ISSUED
<b>Calibration System For Use With Lateral Flow Assay Test Strips</b>							
UNITED STATES	53478.00022US02	NEW	7/5/2005	11/175554	1/24/2012	8101415	ISSUED
EUROPEAN PATENT CON	53478.00022EP01	OTH	7/3/2006	06786269.8	4/6/2016	1910833	ISSUED
UNITED STATES	53478.00022US01	DIV	1/20/2012	13/354949			PUBLISHED
<b>Cytatin C Test Strips</b>							
UNITED STATES	53478.00161PV01	NEW					PROPOSED
<b>Device For Preventing Assay Interference Using Silver Or Lead To Remove The Interferant</b>							
UNITED STATES	53478.00173US01	NEW	8/27/1996	08/703479	8/31/1999	5945345	ISSUED
<b>Diagnostic Multi-Layer Dry Phase Test Strip With Integrated Biosensors</b>							
CHINA	53478.00017CN01	DCA	6/11/2009	200980156888.5	3/11/2015	ZL20098015688 8.5	ISSUED
EUROPEAN PATENT CON	53478.00017EP01	DCA	6/11/2009	09789795.3			PUBLISHED
INDIA	53478.00017IN01	DCA	6/11/2009	3182/KOLNP/2011			PUBLISHED
UNITED STATES	53478.00017US01	DCA	6/11/2009	13/146169			PUBLISHED
WIPO	53478.00017WO01	OTH	6/11/2009	PCT/US2009/0471 06			INACTIVE

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
<b>Diagnostic Test Meter With Bluetooth</b>							
UNITED STATES	53478.00147PV01	NEW					INACTIVE
<b>Diagnostic Test Meter With Near Field Communication</b>							
UNITED STATES	53478.00148PV01	NEW					PROPOSED
<b>Direct blood Pressure Monitors With Wireless Connectivity</b>							
UNITED STATES	53478.00149PV01	NEW					PROPOSED
<b>Direct Measurement Of Cholesterol From Low Density Lipoprotein With Test Strip</b>							
UNITED STATES	53478.00007US04	OTH	10/11/2004	10/962272	10/14/2008	7435577	ISSUED
AUSTRALIA	53478.00007AU01	DCA	2/3/2005	2005209856	9/23/2010	2005209856	ISSUED
BRAZIL	53478.00007BR01	DCA	2/3/2005	PI0507386-3			PENDING
CANADA	53478.00007CA01	DCA	2/3/2005	2554776	12/4/2012	2554776	ISSUED
SWITZERLAND	53478.00007CH02	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
CHINA	53478.00007CN01	DCA	2/3/2005	200580010409.0	7/22/2015	ZL200580010409.0	ISSUED
CHINA	53478.00007CN03	DIV	2/3/2005	201510349145.7			PUBLISHED
GERMANY	53478.00007DE02	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
EURASIAN PATENT	53478.00007EA01	DCA	2/3/2005	200601415	8/29/2008	010414	ISSUED
EUROPEAN PATENT CON	53478.00007EP01	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
UNITED KINGDOM	53478.00007GB02	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
INDONESIA	53478.00007ID01	DCA	2/3/2005	W00200602156			PENDING
ISRAEL	53478.00007IL01	DCA	2/3/2005	177226	12/28/2011	177226	ISSUED
INDIA	53478.00007IN01	DCA	2/3/2005	2210/KOLNP/2006	3/8/2011	246648	ISSUED
ITALY	53478.00007IT02	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
JAPAN	53478.00007JP01	DCA	2/3/2005	2006552209	7/22/2011	4785753	ISSUED
MEXICO	53478.00007MX02	DCA	2/3/2005	PA/a/2006/008714	1/13/2012	294736	ISSUED
POLAND	53478.00007PL02	DCA	2/3/2005	05712615.3	11/26/2014	1725650	ISSUED
WIPO	53478.00007WO01	CEQ	2/3/2005	PCT/US2005/003234			INACTIVE
SOUTH AFRICA	53478.00007ZA01	DCA	2/3/2005	2006/06561	1/30/2008	200606561	ISSUED
AUSTRIA	53478.00007AT01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
BELGIUM	53478.00007BE01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
BRAZIL	53478.00007BR02	DCA	8/17/2005	PI0514495-7			PUBLISHED
CANADA	53478.00007CA02	DCA	8/17/2005	2576453	12/3/2013	2576453	ISSUED
SWITZERLAND	53478.00007CH01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
CHINA	53478.00007CN02	DCA	8/17/2005	200580035466.4	4/4/2012	101228444	ISSUED
GERMANY	53478.00007DE01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
EUROPEAN PATENT CON	53478.00007EP02	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
FRANCE	53478.00007FR01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
UNITED KINGDOM	53478.00007GB01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
INDIA	53478.00007IN02	DCA	8/17/2005	683/KOLNP/2007	2/29/2016	271662	ISSUED
ITALY	53478.00007IT01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
MEXICO	53478.00007MX01	DCA	8/17/2005	MX/a/2007/001925	7/23/2013	315864	ISSUED
POLAND	53478.00007PL01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
SWEDEN	53478.00007SE01	DCA	8/17/2005	05788460.3	8/1/2012	1779119	ISSUED
UNITED STATES	53478.00007US03	CIP	8/17/2005	11/206893	12/1/2009	7625721	ISSUED

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
WIPO	53478.00007WO02	OTH	8/17/2005	PCT/US2005/0294 53			INACTIVE
WIPO	53478.00007WO03	OTH	8/17/2005	PCT/US2005/0294 58			INACTIVE
UNITED STATES	53478.00007US01	DIV	10/16/2009	12/580866	2/4/2014	8642320	ISSUED
UNITED STATES	53478.00007US02	DIV	1/31/2014	14/170268	11/10/2015	9182418	ISSUED

#### Direct Temperature Measurement Of A Test Strip

UNITED STATES	53478.00144US01	NEW	3/14/2013	13/804824			PUBLISHED
CANADA	53478.00144CA01	DCA	3/14/2014	2907831			PENDING
CHINA	53478.00144CN01	DCA	3/14/2014	201480020982.9			PUBLISHED
EUROPEAN PATENT CON	53478.00144EP01	DCA	3/14/2014	14769580.3			PUBLISHED
SOUTH KOREA	53478.00144KR01	DCA	3/14/2014	7029459/2015			PENDING
MEXICO	53478.00144MX01	DCA	3/14/2014	MX/a/2015/012921			PENDING
SAUDI ARABIA	53478.00144SA01	DCA	3/14/2014	515361112			PENDING
WIPO	53478.00144WO01	CEQ	3/14/2014	PCT/US2014/0284 62			INACTIVE

#### Dry Reagent Particle Assay And Device Having Multiple Test Zones And Method Therefor

UNITED STATES	53478.00030US01	CON	4/19/2004	10/826880	12/22/2009	7635597	EXPIRED
---------------	-----------------	-----	-----------	-----------	------------	---------	---------

#### Dry Reagent Strip Configuration, Composition And Method For Multiple Analyte Determination

UNITED STATES	53478.00020US01	CON	3/31/2004	10/816230	1/13/2009	7476548	ISSUED
---------------	-----------------	-----	-----------	-----------	-----------	---------	--------

#### Dry Test Strip With Controlled Flow And Method Of Manufacturing Same

UNITED STATES	53478.00015US01	CIP	10/31/2007	11/933292	6/18/2013	8465696	ISSUED
---------------	-----------------	-----	------------	-----------	-----------	---------	--------

#### Electrochemical Assay For Hemoglobin A1C

UNITED STATES	53478.00153PV01	NEW					PROPOSED
---------------	-----------------	-----	--	--	--	--	----------

#### Electrochemical Assay For Ketones

UNITED STATES	53478.00154US01	NEW					INACTIVE
---------------	-----------------	-----	--	--	--	--	----------

#### Electrochemical Hematocrit Determination By Alternate Current Impedance Phase Angle Determinations

UNITED STATES	53478.00151PV01	NEW	11/25/2014	62/084362			INACTIVE
UNITED STATES	53478.00151US01	FCA	11/25/2015	14/952360			PUBLISHED
WIPO	53478.00151WO01	CEQ	11/25/2015	PCT/US2015/0627 06			PUBLISHED

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
<b>Hand-Held Diagnostic Instrument</b>							
UNITED STATES	53478.00139US01	NEW	2/15/2002	29/155741	1/2/2007	D534444	ISSUED
<b>Health Monitoring And Diagnostic Device And Network-Based Health Assissment And Medical Records Maintenance System</b>							
UNITED STATES	53478.00014US04	FCA	11/8/1999	09/436323	8/5/2003	6602469	ISSUED
UNITED STATES	53478.00014US02	DIV	8/26/2003	10/649293	8/3/2010	7767149	ISSUED
UNITED STATES	53478.00014US03	CON	6/23/2011	13/166968	9/4/2012	8257654	ISSUED
UNITED STATES	53478.00014US01	CON	8/22/2012	13/592143			PUBLISHED
<b>Hybrid Magnetic Particle Fluorescent And UV/VIS Test Strip And Meter Technology</b>							
UNITED STATES	53478.00152PV01	NEW					PROPOSED
<b>Hybrid Strip</b>							
UNITED STATES	53478.00016US02	DCA	6/11/2009	12/997781	6/11/2013	8460539	ISSUED
UNITED STATES	53478.00016US01	CIP	3/15/2013	13/843116			PUBLISHED
CHINA	53478.00016CN01	DCA	2/28/2014	201480021106.8			PUBLISHED
EUROPEAN PATENT CON	53478.00016EP01	DCA	2/28/2014	14768248.8			PUBLISHED
WIPO	53478.00016WO01	CEQ	2/28/2014	PCT/US2014/019476			INACTIVE
HONG KONG	53478.00016HK01	CEQ	3/14/2016	16102899.0			PENDING
<b>Hypertension Biomarker Strip Technology Test Systems</b>							
UNITED STATES	53478.00150PV01	NEW					PROPOSED
<b>Individually Packaged Disposable Blood Testing Unit</b>							
AUSTRIA	53478.00188AT01	NEW	4/26/2013	50290/2013	11/15/2014	514301	ISSUED
EUROPEAN PATENT CON	53478.00188EP05	DCA	4/25/2014	14723747.3			PENDING
WIPO	53478.00188WO02	CEQ	4/25/2014	PCT/EP2014/058497			INACTIVE
<b>Inter Partes Review: Method For Determining HDL Concentration From Whole Blood Or Plasma (Assignee: Polymer Technology Systems, Inc. USPN 7,087,397)</b>							
UNITED STATES	53478.00004	REX	4/24/2015	IPR2015-01109			INACTIVE
UNITED STATES	53478.00006	REX	5/12/2015	IPR2015-01192			INACTIVE
<b>Invetech Concepts</b>							
UNITED STATES	53478.00167PV01	NEW					PROPOSED

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

### Lipid Test Strip With Hematocrit

UNITED STATES	53478.00145PV01	NEW	11/25/2014	62/084351			INACTIVE
UNITED STATES	53478.00145US01	FCA	11/25/2015	14/952015			PUBLISHED
WIPO	53478.00145WO01	CEQ	11/25/2015	PCT/US2015/0627 03			PUBLISHED

### Mechanical Cartridge With Test Strip Fluid Control Features For Use In A Fluid Analyte Meter

BRAZIL	53478.00025BR01	DCA	5/4/2005	PI0510518-8			PUBLISHED
CANADA	53478.00025CA01	DCA	5/4/2005	2564292	8/26/2014	2564292	ISSUED
CHINA	53478.00025CN01	DCA	5/4/2005	200580014226.6	6/20/2012	ZL20058001422 6.6	ISSUED
EUROPEAN PATENT CON	53478.00025EP01	DCA	5/4/2005	05746988.4			PUBLISHED
INDIA	53478.00025IN01	DCA	5/4/2005	4448/CHENP/2006	9/17/2013	257235	ISSUED
JAPAN	53478.00025JP01	DCA	5/4/2005	2007-511573	1/18/2013	5178190	ISSUED
SOUTH KOREA	53478.00025KR01	DIV	5/4/2005	10-2012-7024768	12/26/2013	10-1347472	ISSUED
SOUTH KOREA	53478.00025KR02	DIV	5/4/2005	10-2013-7011997	10/25/2013	10-1324375	ISSUED
SOUTH KOREA	53478.00025KR03	DCA	5/4/2005	10-2006-7025323	5/3/2013	10-1263028	ISSUED
MEXICO	53478.00025MX01	DCA	5/4/2005	PA/a/2006/012707	12/2/2010	281635	ISSUED
NORWAY	53478.00025NO01	DCA	5/4/2005	20065140			PUBLISHED
RUSSIA	53478.00025RU01	DCA	5/4/2005	2006142702	10/30/2009	2370753	ISSUED
UNITED STATES	53478.00025US01	FCA	5/4/2005	11/121972	3/9/2010	7674615	ISSUED
WIPO	53478.00025WO01	CEQ	5/4/2005	PCT/US2005/0155 70			INACTIVE
SOUTH AFRICA	53478.00025ZA01	DCA	5/4/2005	2006/10071	4/30/2008	2006/10071	ISSUED
UNITED STATES	53478.00025US03	OTH	5/2/2006	29/259184	4/17/2007	D540953	ISSUED
HONG KONG	53478.00025HK01	CEQ	12/3/2007	07113201.1	11/9/2012	HK1104854	ISSUED
UNITED STATES	53478.00025US02	CON	3/8/2010	12/661022	11/5/2013	8574919	ISSUED

### Mechanical Device For Mixing A Fluid Sample With A Treatment Solution

UNITED STATES	53478.00024US01	OTH	1/25/2005	11/043510	9/15/2009	7588724	ISSUED
EUROPEAN PATENT CON	53478.00024EP01	DCA	3/7/2005	05724756.1			PUBLISHED
SOUTH KOREA	53478.00024KR01	DCA	3/7/2005	10-2006-7020572	4/28/2011	10-1033375	ISSUED
MEXICO	53478.00024MX01	DCA	3/7/2005	PA/a/2006/009988	5/4/2011	286320	ISSUED
RUSSIA	53478.00024RU01	DCA	3/7/2005	2006135122	10/20/2009	2370211	ISSUED
WIPO	53478.00024WO01	OTH	3/7/2005	PCT/US2005/0072 75			INACTIVE
SOUTH AFRICA	53478.00024ZA01	DCA	3/7/2005	2006/7519	4/30/2008	2006/7519	ISSUED
UNITED STATES	53478.00024US02	CON	8/10/2009	12/462810	7/6/2010	7749770	ISSUED

### Mechanical Device For Mixing A Fluid Sample With A Treatment Solution

UNITED STATES	53478.00026US01	NEW	7/12/2006	11/485743	8/10/2010	7771655	ISSUED
BRAZIL	53478.00026BR01	DCA	6/26/2007	PI0713069-4			PUBLISHED
CANADA	53478.00026CA01	DCA	6/26/2007	2654782	10/8/2013	2654782	ISSUED
EUROPEAN PATENT CON	53478.00026EP01	DCA	6/26/2007	07796534.1			PUBLISHED
INDIA	53478.00026IN01	DCA	6/26/2007	5174/KOLNP/2008			PUBLISHED
MEXICO	53478.00026MX01	DCA	6/26/2007	MX/a/2009/000321	2/21/2012	296506	ISSUED
NORWAY	53478.00026NO01	DCA	6/26/2007	20090669			PUBLISHED
RUSSIA	53478.00026RU01	DCA	6/26/2007	2009104703	2/20/2012	2442968	ISSUED

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
WIPO	53478.00026WO01	CEQ	6/26/2007	PCT/US2007/0149 86			INACTIVE

#### Method And Device For Blood Separation In A Diagnostic Device

JAPAN	53478.00172JP01	DCA	11/27/1996	520699/97	11/14/2008	4216335	ISSUED
-------	-----------------	-----	------------	-----------	------------	---------	--------

#### Method And Device For Measuring Reflected Optical Radiation

JAPAN	53478.00029JP01	DCA	4/30/1997	1997-539180	7/13/2007	3984651	ISSUED
JAPAN	53478.00029JP02	DIV	4/30/1997	2007-119451	7/16/2010	4551421	ISSUED
WIPO	53478.00029WO01	CEQ	4/30/1997	PCT/US1997/0072 23			EXPIRED
UNITED STATES	53478.00029US01	CON	7/21/2005	11/188079	2/17/2009	7492461	EXPIRED
UNITED STATES	53478.00029US02	OTH	9/22/2008	12/235371	10/25/2011	8045169	ISSUED

#### Method And Device For Producing A Predetermined Distribution Of Detectable Change In Assays

JAPAN	53478.00174JP01	DCA	5/14/1997	519784/98	12/5/2008	4225576	ISSUED
-------	-----------------	-----	-----------	-----------	-----------	---------	--------

#### Method For Determining Concentration Of Creatine In A Bodily Fluid

UNITED STATES	53478.00138US01	FCA	4/30/2003	10/426236	8/1/2006	7083939	ISSUED
---------------	-----------------	-----	-----------	-----------	----------	---------	--------

#### Method For Determining HDL Cholesterol Concentration From Whole Blood

GERMANY	53478.00009DE01	DCA	12/23/2002	10005559.9	5/28/2014	2221621	ISSUED
EUROPEAN PATENT CON	53478.00009EP01	DIV	12/23/2002	10005559.9	5/28/2014	2221621	ISSUED
UNITED KINGDOM	53478.00009GB01	DCA	12/23/2002	10005559.9	5/28/2014	2221621	ISSUED
ITALY	53478.00009IT01	DCA	12/23/2002	10005559.9	5/28/2014	2221621	ISSUED

#### Method For Determining HDL Concentration From Whole Blood Or Plasma

UNITED STATES	53478.00009US01	NEW	12/23/2002	10/329044	8/8/2006	7087397	ISSUED
---------------	-----------------	-----	------------	-----------	----------	---------	--------

#### Methods And Systems For Point Of Care Bodily Fluid Analysis

UNITED STATES	53478.00028US01	NEW	1/16/2004	10/759547	12/19/2006	7150995	ISSUED
---------------	-----------------	-----	-----------	-----------	------------	---------	--------

#### Methods For Humidity Indication Directly In A Test Strip

UNITED STATES	53478.00159PV01	NEW					PROPOSED
---------------	-----------------	-----	--	--	--	--	----------

#### Methods, Devices, And Systems For Glycated Hemoglobin Analysis

UNITED STATES	53478.00143US01	DCA	7/20/2009	13/054543			PUBLISHED
---------------	-----------------	-----	-----------	-----------	--	--	-----------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
<b>Mirror Image Amperometrics Strip</b>							
UNITED STATES	53478.00163PV01	NEW					PROPOSED
<b>Novel A1C Conjugates</b>							
UNITED STATES	53478.00168PV01	NEW					PROPOSED
<b>Point-Of-Care Reflectance-Based HCT Detection</b>							
UNITED STATES	53478.00160PV01	NEW					PROPOSED
<b>Sample Pad System For Controlling Fluid Movement Between A Sample Receiving Pad And A Test Strip</b>							
CANADA	53478.00027CA01	DCA	6/5/2007	2652681			PENDING
GERMANY	53478.00027DE01	DCA	6/7/2007	07011195.0	12/1/2010	1865323	ISSUED
EUROPEAN PATENT CON	53478.00027EP01	OTH	6/7/2007	07011195.0	12/1/2010	1865323	ISSUED
<b>Self-Contained Test Unit For Testing Body Fluids</b>							
UNITED STATES	53478.00177	FCA	8/1/2007	11/832475	12/7/2010	7846110	ISSUED
CANADA	53478.00188CA02	DCA	8/2/2007	2657511			PENDING
EUROPEAN PATENT CON	53478.00188EP03	OTH	8/2/2007	07836417.1			PUBLISHED
UNITED KINGDOM	53478.00188GB01	DCA	8/2/2007	GB1420058.8			PUBLISHED
<b>Slimline Health monitoring And Diagnostic Device</b>							
UNITED STATES	53478.00140US01	NEW	11/7/2000	29/132357	7/2/2002	D459811	EXPIRED
<b>System And Method For Packaging Dry Test Strips</b>							
UNITED STATES	53478.00141US01	DCA	6/17/2009	12/999905			INACTIVE
<b>Systems And Methods For A Blood Collector With Enhanced Volume Using Capillary Techniques</b>							
UNITED STATES	53478.00207PV01	NEW	2/17/2016	62/296467			PENDING
<b>Systems And Methods For A Capture Zone With Improved Stability</b>							
UNITED STATES	53478.00197PV01	NEW	12/22/2015	62/271220			PENDING
<b>Systems And Methods For A Lateral Flow Ethyl Glucuronide Assay</b>							
UNITED STATES	53478.00199PV01	NEW	12/22/2015	62/271226			PENDING



COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

### Systems And Methods For A Lateral Flow Ethyl Sulfate Assay

UNITED STATES	53478.00200PV01	NEW	12/22/2015	62/271228			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For A Lateral Flow Test Strip Holder

UNITED STATES	53478.00191PV01	NEW	9/29/2015	62/234528			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For A Multi-Chambered Sampler

UNITED STATES	53478.00214PV01	NEW	5/17/2016	62/337557			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For A Versatile Electrochemical Test Strip That May Include One Or More Assays For Different Analytes In The Same Test Strip

UNITED STATES	53478.00196PV01	NEW	12/17/2015	62/268962			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For An Electrochemical Phenylalanine Assay

UNITED STATES	53478.00208PV01	NEW					INACTIVE
---------------	-----------------	-----	--	--	--	--	----------

### Systems And Methods For An Electrochemical Strip For Detecting A Percentage Of Glycated Hemoglobin And Eliminating Hemoglobin Variant Bias

UNITED STATES	53478.00204PV01	NEW	12/28/2015	62/271759			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For Artificial Test Strip Controls

UNITED STATES	53478.00165PV01	NEW	4/7/2015	62/144233			INACTIVE
UNITED STATES	53478.00165US01	FCA	4/7/2016	15/093236			PENDING
WIPO	53478.00165WO01	CEQ	4/7/2016	PCT/US2016/0264 30			PENDING

### Systems And Methods For Automatic Reporting Of Point-Of-Care (POC) Test Results

UNITED STATES	53478.00170PV01	NEW	3/13/2015	62/132863			INACTIVE
UNITED STATES	53478.00170US01	FCA	3/4/2016	15/061845			PENDING
WIPO	53478.00170WO01	CEQ	3/4/2016	PCT/US2016/0210 40			PENDING

### Systems And Methods For Blood Sample Preservation And Hematocrit Separation

UNITED STATES	53478.00185PV01	NEW	9/1/2015	62/212991			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

**Systems And Methods For Conjugate Preparation Of 25-Hydroxy Vitamin D3 And D2 And Compositions Thereof**

UNITED STATES	53478.00206PV01	NEW	4/1/2016	62/317259			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

**Systems And Methods For Controlling Excessive Fluid Flow In A Cassette Designed To Receive A Fluid Sample**

UNITED STATES	53478.00186PV01	NEW	9/2/2015	62/213469			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

**Systems And Methods For Distinguishing Cotinine From Anabesine In A Point-Of-Care Testing Device**

UNITED STATES	53478.00068PV01	NEW	5/29/2015	62/168597			INACTIVE
---------------	-----------------	-----	-----------	-----------	--	--	----------

UNITED STATES	53478.00068PV02	OTH	6/3/2015	62/170390			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

UNITED STATES	53478.00068US01	FCA	5/27/2016	15/167533			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

WIPO	53478.00068WO01	CEQ	5/27/2016	PCT/US2016/0347 86			PENDING
------	-----------------	-----	-----------	-----------------------	--	--	---------

**Systems And Methods For Electrochemical A1C Detection And Quantification**

UNITED STATES	53478.00193PV01	NEW	12/17/2015	62/268959			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

**Systems And Methods For Electrochemical Aspartate Transaminase (AST) And Alanine Transaminase (ALT) Detection And Quantification**

UNITED STATES	53478.00203PV01	NEW	12/28/2015	62/271753			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

**Systems And Methods For Electrochemical Creatinine Assays**

UNITED STATES	53478.00209PV01	NEW	4/1/2016	62/316323			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

**Systems And Methods For Electrochemical Ketone Detection And Measurement**

UNITED STATES	53478.00005PV01	NEW	5/7/2015	62/158446			INACTIVE
---------------	-----------------	-----	----------	-----------	--	--	----------

UNITED STATES	53478.00005US01	FCA	4/20/2016	15/134156			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

WIPO	53478.00005WO01	CEQ	4/20/2016	PCT/US2016/0284 69			PENDING
------	-----------------	-----	-----------	-----------------------	--	--	---------

**Systems And Methods For Electrochemical Phenylalanine Detection And Quantification**

UNITED STATES	53478.00202PV01	NEW	12/22/2015	62/271229			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

**Systems And Methods For Electrochemical Triglycerides Assays**

UNITED STATES	53478.00211PV01	NEW	4/13/2016	62/322093			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

### Systems And Methods For Enzymatic A1C Detection And Quantification

UNITED STATES	53478.00192PV01	NEW	12/17/2015	62/268956			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For Improving The Accuracy Of Lateral Flow Tests Using A Four-Strip Cartridge

UNITED STATES	53478.00157PV01	NEW	1/23/2015	62/107111			INACTIVE
UNITED STATES	53478.00157US01	FCA	1/22/2016	15/004570			PENDING
WIPO	53478.00157WO01	CEQ	1/22/2016	PCT/US2016/014568			PENDING

### Systems And Methods For Interference Correction From Hemoglobin Variants

UNITED STATES	53478.00195PV01	NEW	12/4/2015	62/263478			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For Interference Correction From Hemoglobin Variants

UNITED STATES	53478.00195PV02	NEW	4/14/2016	62/322687			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For Non-Blood Calibrators Optionally Including MgSO4

UNITED STATES	53478.00164PV01	NEW	4/10/2015	62/146080			INACTIVE
---------------	-----------------	-----	-----------	-----------	--	--	----------

### Systems And Methods For Non-Fasting LDL Cholesterol Assays

BRAZIL	53478.00019BR01	DCA	5/1/2013	BR112013025913-2			PENDING
CANADA	53478.00019CA01	DCA	5/1/2013	2872525			PENDING
CHINA	53478.00019CN01	DCA	5/1/2013	201380000791.1			PUBLISHED
GERMANY	53478.00019DE01	DCA	5/1/2013	112013002316.4			PUBLISHED
EUROPEAN PATENT CON	53478.00019EP01	DCA	5/1/2013	13785323.0			PUBLISHED
UNITED KINGDOM	53478.00019GB01	DCA	5/1/2013	GB1313383.0			PUBLISHED
INDIA	53478.00019IN01	DCA	5/1/2013	6941/CHENP/2013			PUBLISHED
MEXICO	53478.00019MX01	DCA	5/1/2013	MX/s/2013/012368			PUBLISHED
PHILIPPINES	53478.00019PH01	DCA	5/1/2013	1-2014-502463			PUBLISHED
RUSSIA	53478.00019RU01	DCA	5/1/2013	2014148800			PENDING
WIPO	53478.00019WO01	CEQ	5/1/2013	PCT/US2013/039082			INACTIVE

### Systems And Methods For Non-Fasting LDL Cholesterol Assays

UNITED STATES	53478.00019US01	FCA	5/1/2013	13/874971	12/8/2015	9207184	ISSUED
UNITED STATES	53478.00019US02	CON	12/7/2015	14/961634			PUBLISHED

### Systems And Methods For Point-Of-Care Determination OF HDL-C And HDL-P

UNITED STATES	53478.00189PV01	NEW	9/29/2015	62/234525			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

### Systems And Methods For Point-Of-Care Determination Of LDL-C And LDL-P

UNITED STATES	53478.00190PV01	NEW	9/29/2015	62/234527			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For Point-Of-Care HDL And LDL Particle Assay

UNITED STATES	53478.00205PV01	NEW	12/17/2015	62/268971			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For Quantification Of Creatinine Using A Creatinine-Protein Conjugate

UNITED STATES	53478.00198PV01	NEW	12/22/2015	62/271223			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

### Systems And Methods For Reagentless Test Strips

UNITED STATES	53478.00187PV01	NEW	9/1/2015	62/212994			PENDING
---------------	-----------------	-----	----------	-----------	--	--	---------

### Systems and Methods for Remote Calibration of Analyzers and Delivery of Calibration Curves

UNITED STATES	53478.00210PV01	NEW	4/13/2016	62/322089			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods For Temperature Correction In Test Strips For Enzyme Detection

UNITED STATES	53478.00162PV01	NEW	1/30/2015	62/110015			INACTIVE
UNITED STATES	53478.00162US01	FCA	2/1/2016	15/012348			PENDING
WIPO	53478.00162WO01	CEQ	2/1/2016	PCT/US2016/0159 56			PENDING

### Systems And Methods For Test Strips With Extended Dynamic Ranges

CANADA	53478.00142CA01	DCA	3/10/2014	2907938			PENDING
CHINA	53478.00142CN01	DCA	3/10/2014	201480020591.7			PUBLISHED
EUROPEAN PATENT CON	53478.00142EP01	DCA	3/10/2014	14779788.0			PUBLISHED
HONG KONG	53478.00142HK01	CEQ	3/10/2014	16106029.4			PENDING
UNITED STATES	53478.00142US01	FCA	3/10/2014	14/203189			PUBLISHED
WIPO	53478.00142WO01	OTH	3/10/2014	PCT/US2014/0226 61			INACTIVE

### Systems And Methods For Vitamin D Dissociating Compounds

UNITED STATES	53478.00215PV01	NEW	5/26/2016	62/342079			PENDING
---------------	-----------------	-----	-----------	-----------	--	--	---------

### Systems And Methods Of Using Boron Affinity To Eliminate Hemoglobin Variant Bias

UNITED STATES	53478.00201PV01	NEW	12/17/2015	62/268967			PENDING
---------------	-----------------	-----	------------	-----------	--	--	---------

COUNTRY	REFERENCE #	TYPE	FILED	SERIAL #	ISSUED	PATENT #	STATUS
---------	-------------	------	-------	----------	--------	----------	--------

**Systems, Compositions, And Methods Of Lipid Panel Test Controls Utilizing Particles That Mimic Hematocrit**

UNITED STATES	53478.00156PV01	NEW	1/26/2015	62/107851			INACTIVE
UNITED STATES	53478.00156US01	FCA	1/22/2016	15/004589			PENDING
WIPO	53478.00156WO01	CEQ	1/22/2016	PCT/US2016/014575			PENDING

**Test Strip And Method For Determining LDL Cholesterol Concentration From Whole Blood**

SOUTH AFRICA	53478.00137ZA01	DCA	9/16/2003	2005/02214	5/31/2006	2005/02214	ISSUED
--------------	-----------------	-----	-----------	------------	-----------	------------	--------

**Test Strip For Determining Concentration Of Multiple Analytes In A Single Fluid Sample**

AUSTRALIA	53478.00012AU01	DCA	12/30/2002	2002364609	7/17/2008	2002364609	ISSUED
CANADA	53478.00012CA01	DCA	12/30/2002	2471726	4/5/2011	2471726	ISSUED
SWITZERLAND	53478.00012CH01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
GERMANY	53478.00012DE01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
EUROPEAN PATENT CON	53478.00012EP01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
FRANCE	53478.00012FR01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
UNITED KINGDOM	53478.00012GB01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
ITALY	53478.00012IT01	DCA	12/30/2002	02799993.7	12/17/2014	1474692	ISSUED
MEXICO	53478.00012MX01	DCA	12/30/2002	PA/a/2004/006367	6/10/2009	4006367	ISSUED
UNITED STATES	53478.00012US02	FCA	12/30/2002	10/334043	2/24/2009	7494818	ISSUED
WIPO	53478.00012WO01	CEQ	12/30/2002	PCT/US2002/041672			INACTIVE
SOUTH AFRICA	53478.00012ZA01	DCA	12/30/2002	2004/04929	10/25/2006	2004/04929	ISSUED
UNITED STATES	53478.00012US01	CON	6/22/2004	10/873415	5/20/2008	7374719	ISSUED

**Test Strip For Determining Concentration Of Triglycerides**

AUSTRIA	53478.00010AT01	DCA	12/30/2002	02794458.6	2/13/2008	386266	ISSUED
BELGIUM	53478.00010BE01	DCA	12/30/2002	02794458.6	2/13/2008	1459064	ISSUED
GERMANY	53478.00010DE01	DCA	12/30/2002	02794458.6	2/13/2008	1459064	ISSUED
EUROPEAN PATENT CON	53478.00010EP01	DCA	12/30/2002	02794458.6	2/13/2008	1459064	ISSUED
FRANCE	53478.00010FR01	DCA	12/30/2002	02794458.6	2/13/2008	1459064	ISSUED
ITALY	53478.00010IT01	DCA	12/30/2002	02794458.6	2/13/2008	1459064	ISSUED

**Vent Configuration For A Blood Sampler**

UNITED STATES	53478.00067US01	FCA	8/16/2012	13/587439	11/10/2015	9180455	ISSUED
---------------	-----------------	-----	-----------	-----------	------------	---------	--------

END OF REPORT

TOTAL ITEMS SELECTED

307

SCHEDULE B

Trademarks

See attached.

Polymer Technology Systems, Inc.

Trademark Report By Title  
Search Criteria

Printed: 7/15/2016

Client ID 53478

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
---------	-------------	-------	-------	--------	-------	--------	---------

**A1CNOW**

CANADA	53478.00131	11/2/2001	1121145	10/8/2004	TMA622236	REGISTERED	N/A
UNITED STATES	53478.00077	6/15/2010	85/063294	1/18/2011	3908062	REGISTERED	05, 10

**A1CNOW+**

ARGENTINA	53478.00136	5/8/2008	2822830			PENDING	
ARGENTINA	53478.00078	5/8/2008	2822831	5/27/2009	2290464	REGISTERED	
AUSTRALIA	53478.00079	8/8/2006	897475	4/5/2007	897475	REGISTERED	10
BOLIVIA	53478.00080	7/5/2011	SM03473-2011	2/15/2012	133611-C	REGISTERED	
BOSNIA AND HERZEGO	53478.00081	4/1/2011	BAZ1115504A	7/26/2013	BAZ1115504A	REGISTERED	05, 10
BRAZIL	53478.00083	5/19/2008	829741380	9/8/2010	829741380	REGISTERED	
BRAZIL	53478.00082	5/19/2008	829741402	9/8/2010	829741402	REGISTERED	
CANADA	53478.00084	5/6/2008	1394401	8/6/2009	TMA744831	REGISTERED	N/A
CANADA	53478.00085	2/28/2008	1385321	8/11/2009	TMS744997	REGISTERED	N/A
CHINA	53478.00087	5/8/2008	6708706	5/14/2010	6708706	REGISTERED	
CHINA	53478.00086	5/8/2008	6708707	3/28/2010	6708707	REGISTERED	10
COSTA RICA	53478.00088	7/4/2011	2011-006249	3/23/2012	216.996	REGISTERED	
ECUADOR	53478.00089	7/4/2011	2011-6577	2/7/2012	1441-12	REGISTERED	
EGYPT	53478.00091	5/11/2008	216472	2/7/2010	216472	REGISTERED	
EGYPT	53478.00090	5/11/2008	216473	6/5/2010	216473	REGISTERED	
EL SALVADOR	53478.00092	7/7/2011	2011111033	11/22/2012	234 BOOK 200	REGISTERED	10
EUROPEAN UNION (EU)	53478.00093	8/8/2006	897475	8/23/2007	897475	REGISTERED	10
GERMANY	53478.00094	5/8/2008	3020080303336	11/3/2008	302008030333	REGISTERED	05, 10
GREECE	53478.00095	2/18/2010	F154341	12/16/2010	F154341	REGISTERED	05, 10
HONDURAS	53478.00096	7/12/2011	23031-11	11/21/2011	118066	REGISTERED	
HONG KONG	53478.00097	5/7/2008	301111120	12/17/2008	301111120	REGISTERED	05, 10
INDIA	53478.00099	6/27/2008	1704328	2/4/2011	1704328	REGISTERED	05
INDIA	53478.00098	6/27/2008	1704329	2/4/2011	1704329	REGISTERED	10
INDONESIA	53478.00100	8/7/2008	D00-200-024752	5/7/2010	IDM000256259	REGISTERED	05, 10
ITALY	53478.00101	5/8/2008	RM2008C002880	8/18/2010	0001328806	REGISTERED	05, 10
JAPAN	53478.00102	8/8/2006	897475	10/9/2008	897475	REGISTERED	10
JAPAN	53478.00103	5/7/2008	2008-034848	1/9/2009	5194224	REGISTERED	05, 10

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
MALAYSIA	53478.00106	5/7/2008	08008872	1/21/2010	08008872	REGISTERED	05
MALAYSIA	53478.00105	5/7/2008	08008873	2/3/2010	08008873	REGISTERED	10
MEXICO	53478.00108	5/7/2008	932092	5/23/2008	1040868	REGISTERED	05
MEXICO	53478.00107	5/7/2008	932093	5/23/2008	1040869	REGISTERED	10
NICARAGUA	53478.00109	7/8/2011	2001-002344	9/30/2013	2013099195	REGISTERED	
NIGERIA	53478.00110	7/4/2011	F/TM/2011/11960			INACTIVE	
PAKISTAN	53478.00112	5/30/2008	251465	8/3/2011	251465	REGISTERED	
PAKISTAN	53478.00111	5/30/2008	251464	3/19/2012	251464	REGISTERED	
PANAMA	53478.00113	7/18/2011	202351	7/18/2011	202351	REGISTERED	
PERU	53478.00114	7/1/2011	260191-2011	10/5/2011	180422	REGISTERED	
POLAND	53478.00115	2/18/2010	366489	4/8/2011	235985	REGISTERED	05, 10
RUSSIA	53478.00118	5/8/2008	2008714448	7/8/2009	382755	REGISTERED	05, 10
SAUDI ARABIA	53478.00120	5/10/2008	130546	4/17/2009	1061/5	REGISTERED	
SAUDI ARABIA	53478.00119	5/10/2008	130547	4/17/2009	1061/6	REGISTERED	
SERBIA	53478.00121	3/30/2011	Z-471/11	3/30/2011	63291	REGISTERED	05, 10
SINGAPORE	53478.00122	8/8/2006	897475	5/15/2007	T0622428B	REGISTERED	10
SINGAPORE	53478.00123	5/7/2008	T0805933E	8/8/2008	T0805933E	REGISTERED	05, 10
SOUTH KOREA	53478.00116	8/8/2006	897475	10/5/2007	897475	REGISTERED	10
SOUTH KOREA	53478.00117	5/9/2008	4020080022498	2/25/2009	4007809180000	REGISTERED	05, 10
SRI LANKA	53478.00124	6/2/2011	163177			PENDING	
THAILAND	53478.00125	5/27/2010	768059			INACTIVE	
UNITED ARAB EMR	53478.00127	5/13/2008	112651	4/27/2008	102584	REGISTERED	05
UNITED ARAB EMR	53478.00126	5/13/2008	112652	5/4/2010	102904	REGISTERED	10
UNITED KINGDOM	53478.00128	5/7/2008	2486898	11/14/2008	2486898	REGISTERED	05, 10
UNITED STATES	53478.00129	7/11/2006	78/927177	5/8/2007	3239736	REGISTERED	10
UNITED STATES	53478.00130	5/30/2008	77/487362	12/16/2008	3546838	REGISTERED	05, 10
WIPO	53478.00104	8/8/2006	A0005492	8/8/2006	897475	REGISTERED	10

#### A1CNOW+ (and Design)

JAPAN	53478.00133	2/5/2009	2009-013545	11/20/2009	5281650	REGISTERED	05, 10
-------	-------------	----------	-------------	------------	---------	------------	--------

#### A1CNOW+ (in Cyrillic)

RUSSIA	53478.00134	2/25/2010	2010705462	2/7/2011	429681	REGISTERED	05, 10
--------	-------------	-----------	------------	----------	--------	------------	--------



COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
<b>A1CNOW+ (in Kana)</b>							
JAPAN	53478.00132	2/6/2009	2009-013546	10/30/2009	5276909	REGISTERED	05, 10
<b>CARDIOCHEK</b>							
BRAZIL	53478.00221BR01	2/7/2013	840414773			PENDING	09
MEXICO	53478.00227MX01		1090418			PENDING	09
MEXICO	53478.00228MX01	6/12/2013	1382363	10/29/2013	1407428	REGISTERED	10
SOUTH KOREA	53478.00229KR01	1/16/2013	N/A	1/2/2014	40105430000	REGISTERED	09
UNITED STATES	53478.00232US01	5/22/2013	85/939164	12/24/2013	4455007	REGISTERED	09
<b>CARDIOCHEK CONNECT</b>							
UNITED STATES	53478.00064	5/9/2011	85/316216	7/17/2012	4173939	REGISTERED	09
<b>CARDIOCHEK CONNECT (Stylized w/Design)</b>							
UNITED STATES	53478.00065	5/9/2011	85/316224	7/31/2012	4181840	REGISTERED	09
<b>CARDIOCHEK LINK</b>							
UNITED STATES	53478.00076	7/16/2008	77/523266	9/8/2009	3681134	REGISTERED	09
<b>CARDIOCHEK</b>							
AUSTRALIA	53478.00175	11/2/2005	880515	9/21/2006	880515	REGISTERED	10
CANADA	53478.00069	4/8/2011	1522946	4/5/2012	TMA821639	REGISTERED	N/A
CHINA	53478.00070	11/2/2005	880515	3/24/2008	880515	REGISTERED	10
EUROPEAN UNION (EU)	53478.00031	7/3/2007	006062897	8/21/2008	006062897	REGISTERED	10
FINLAND	53478.00032	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
GERMANY	53478.00033	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
HUNGARY	53478.00035	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
INDIA	53478.00036	11/6/2009	1881037	5/3/2016	1881037	REGISTERED	10
IRELAND	53478.00037	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
JAPAN	53478.00038	11/2/2005	0880515	10/4/2013	880515	REGISTERED	10
RUSSIA	53478.00071	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
SERBIA	53478.00072	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
SINGAPORE	53478.00040	11/2/2005	880515	11/2/2005	T0608524Z	REGISTERED	10
SWEDEN	53478.00041	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
SYRIA	53478.00042	11/2/2005	880515	11/2/2005	880515	REGISTERED	10

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
UNITED KINGDOM	53478.00034	11/2/2005	880515	11/2/2005	880515	REGISTERED	10
UNITED STATES	53478.00043	5/2/2005	78/621442	4/25/2006	3085202	REGISTERED	10
WIPO	53478.00039	11/2/2005	880515	11/2/2005	880515	REGISTERED	10

### CARDIOLINK

HONG KONG	53478.00213HK01	5/2/2006	300630927	11/2/2006	300630927	REGISTERED	09
MEXICO	53478.00213MX01	5/2/2006	780350	8/28/2006	949167	REGISTERED	09
TAIWAN	53478.00231TW01	5/2/2006	Awaiting	4/16/2007	1258200	REGISTERED	

### CHOLESTRON

CANADA	53478.00212CA01	2/17/1989	0625726	3/20/1992	TMA395762	REGISTERED	NA
--------	-----------------	-----------	---------	-----------	-----------	------------	----

### EGLU

UNITED STATES	53478.00233US01	4/21/2013	85/910240	9/23/2014	4610651	REGISTERED	05
---------------	-----------------	-----------	-----------	-----------	---------	------------	----

### MEMO CHIP

AUSTRALIA	53478.00057	5/27/2008	974550	5/27/2008	974550	REGISTERED	09
CHINA	53478.00058	5/27/2008	974550	5/27/2008	974550	REGISTERED	09
EUROPEAN UNION (EU)	53478.00059	5/27/2008	974550	5/27/2008	974550	REGISTERED	09
JAPAN	53478.00060	5/27/2008	974550	5/27/2008	974550	REGISTERED	09
TURKEY	53478.00062	5/27/2008	974550	5/27/2008	974550	REGISTERED	09
UNITED STATES	53478.00063	11/26/2007	77/336655	5/26/2009	3625304	REGISTERED	05
WIPO	53478.00061	5/27/2008	A0012572	5/27/2008	974550	REGISTERED	09

### METRIKA

UNITED STATES	53478.00066	6/26/1995	74/694138	11/4/1997	2111089	REGISTERED	10
---------------	-------------	-----------	-----------	-----------	---------	------------	----

### PTS

UNITED STATES	53478.00056	6/8/2005	78/646600	9/25/2007	3297266	REGISTERED	05, 10
---------------	-------------	----------	-----------	-----------	---------	------------	--------

### PTS (Logo)

UNITED STATES	53478.00075					PROPOSED	09
---------------	-------------	--	--	--	--	----------	----

### PTS (Stylized w/Design)

ARGENTINA	53478.00044	10/6/2008	2863631	9/25/2009	2317229	REGISTERED	10
AUSTRALIA	53478.00045	9/11/2008	0984926	5/28/2009	0984926	REGISTERED	10

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
BRAZIL	53478.00046	10/10/2008	830066489	6/11/2013	830066489	REGISTERED	10
CANADA	53478.00047	9/24/2008	1412035	5/13/2010	TMA766655	REGISTERED	N/A
EUROPEAN UNION (EU)	53478.00048	9/11/2008	0984926	11/19/2009	0984926	REGISTERED	10
INDIA	53478.00049	9/17/2008	1733693	9/5/2013	1733693	REGISTERED	10
MEXICO	53478.00051	9/19/2008	962104	3/19/2009	1090418	REGISTERED	10
SOUTH AFRICA	53478.00052	9/12/2008	2008/21404	8/22/2011	2008/21404	REGISTERED	10
SOUTH KOREA	53478.00050	9/11/2008	0984926	11/19/2009	0984926	REGISTERED	10
TURKEY	53478.00053	9/11/2008	0984926	2/10/2010	0984926	REGISTERED	10
UNITED STATES	53478.00054	4/11/2008	77/446385	3/10/2009	3585823	INACTIVE	10
UNITED STATES	53478.00074					PROPOSED	05
WIPO	53478.00073	9/11/2008	A0013764	9/11/2008	0984926	REGISTERED	10

### PTS CONNECT

AUSTRALIA	53478.00219AU01	3/16/2016	1297102			PENDING	09
BENELUX	53478.00219BX01	3/16/2016	1297102			PENDING	09
CANADA	53478.00226CA01	3/17/2016	1772996			PENDING	09
CHINA	53478.00219CN01	3/16/2016	1297102			PENDING	09
EUROPEAN UNION (EU)	53478.00219EM01	3/16/2016	1297102			PENDING	09
INDIA	53478.00219IN01	3/16/2016	1297102			PENDING	09
JAPAN	53478.00219JP01	3/16/2016	1297102			PENDING	09
MEXICO	53478.00219MX01	3/16/2016	1297102			PENDING	09
NEW ZEALAND	53478.00219NZ01	3/16/2016	1297102			PENDING	09
RUSSIA	53478.00219RU01	3/16/2016	1297102			PENDING	09
SINGAPORE	53478.00219SG01	3/16/2016	1297102			PENDING	09
SOUTH KOREA	53478.00219KR01	3/16/2016	1297102			PENDING	09
SWITZERLAND	53478.00219CH01	3/16/2016	1297102			PENDING	09
UNITED STATES	53478.00234US01	2/25/2016	86/919759			PUBLISHED	09
WIPO	53478.00219WO01	3/16/2016	1297102	3/16/2016	1297102	REGISTERED	09

### PTS DETECT

AUSTRALIA	53478.00218AU01	3/16/2016	1297099			PENDING	10
BENELUX	53478.00218BX01	3/16/2016	1297099			PENDING	10
CANADA	53478.00225CA01	3/17/2016	1772995			PENDING	10
CHINA	53478.00218CN01	3/16/2016	1297099			PENDING	10
EUROPEAN UNION (EU)	53478.00218EU01	3/16/2016	1297099			PUBLISHED	10

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
INDIA	53478.00218IN01	3/16/2016	1297099			PENDING	10
JAPAN	53478.00218JP01	3/16/2016	1297099			PENDING	10
MEXICO	53478.00218MX01	3/16/2016	1297099			PENDING	10
NEW ZEALAND	53478.00218NZ01	3/16/2016	1297099			PUBLISHED	10
RUSSIA	53478.00218RU01	3/16/2016	1297099			PENDING	10
SINGAPORE	53478.00218SG01	3/16/2016	1297099			PENDING	10
SOUTH KOREA	53478.00218KR01	3/16/2016	1297099			PENDING	10
SWITZERLAND	53478.00218CH01	3/16/2016	1297099			PENDING	10
UNITED STATES	53478.00236US01	9/18/2015	86/760806	5/31/2016	4968130	REGISTERED	10
WIPO	53478.00218WO01	3/16/2016	1297099	3/16/2016	1297099	REGISTERED	10

### PTS PANELS

AUSTRALIA	53478.00216AU01	10/17/2012	1151771	7/10/2013	1151771	REGISTERED	05
BRAZIL	53478.00222BR01	2/7/2013	840414790			PENDING	05
CANADA	53478.00223CA01	10/29/2012	1600052	11/25/2013	TMA865871	REGISTERED	05
CHINA	53478.00216CN01	10/17/2012	1151771	1/2/2014	1151771	REGISTERED	05
EUROPEAN UNION (EU)	53478.00216EU01	10/17/2012	1151771	1/2/2014	1151771	REGISTERED	05
JAPAN	53478.00216JP01	10/17/2012	1151771	9/26/2013	1151771	REGISTERED	05
RUSSIA	53478.00216RU01	10/17/2012	1151771			INACTIVE	05
SOUTH KOREA	53478.00216KR01	10/17/2012	1151771	2/20/2014	1151771	REGISTERED	05
SOUTH KOREA	53478.00230KR01	1/16/2013	401054610000	1/2/2014	401054610000	REGISTERED	05
SWITZERLAND	53478.00216CH01	10/17/2012	1151771	5/15/2014	1151771	REGISTERED	05
UNITED STATES	53478.00055	5/31/2005	78/640726	12/5/2006	3179677	REGISTERED	05
WIPO	53478.00216WO01	10/17/2012	1151771	10/17/2012	1151771	REGISTERED	05

### PTS POD

AUSTRALIA	53478.00217AU01	3/16/2016	1296729			PUBLISHED	10
BENELUX	53478.00217BX01	3/16/2016	1296729			PENDING	10
CANADA	53478.00224CA01	3/17/2016	1772994			PENDING	n/a
CHINA	53478.00217CN01	3/16/2016	1296729			PENDING	10
EUROPEAN UNION (EU)	53478.00217EU01	3/16/2016	1296729			PUBLISHED	10
INDIA	53478.00217IN01	3/16/2016	1296729			PENDING	10
JAPAN	53478.00217JP01	3/16/2016	1296729			PENDING	10
MEXICO	53478.00217MX01	3/16/2016	1296729			PENDING	10
NEW ZEALAND	53478.00217NZ01	3/16/2016	1296729			PUBLISHED	10

COUNTRY	REFERENCE #	FILED	APP #	REG DT	REG #	STATUS	CLASSES
RUSSIA	53478.00217RU01	3/16/2016	1296729			PENDING	10
SINGAPORE	53478.00217SG01	3/16/2016	1296729			PENDING	10
SOUTH KOREA	53478.00217KR01	3/16/2016	1296729			PENDING	10
SWITZERLAND	53478.00217CH01	3/16/2016	1296729			PENDING	10
UNITED STATES	53478.00235US01	9/22/2015	86/763927	5/31/2016	4968208	REGISTERED	10
WIPO	53478.00217WO01	3/16/2016	1296729	3/16/2016	1296729	REGISTERED	10

END OF REPORT

TOTAL ITEMS SELECTED =

170

SCHEDULE C

Licenses

See attached.

**Exhibit C**  
**Licenses**

<b>Agreement</b>	<b>Parties</b>	<b>Effective Date</b>
Exclusive Patent License Agreement	Inverness Medical Switzerland GmbH and Metrika, Inc.	7/15/2004
Amendment to Exclusive Patent License Agreement (Church & Dwight patents)	Inverness Medical Innovations Inc. and Bayer HealthCare LLC, Diabetes Care	1/25/2010
Patent Assignment and License Agreement	Omniquant Medical Inc. and Metrika, Inc.	6/20/2006
Development/Option & License Agreement	Warner-Lambert Company (Warner-Lambert Consumer Healthcare) and Metrika, Inc.	7/2/1999
Patent License Agreement	Church & Dwight, Inc. and Bayer Healthcare LLC	12/31/2009

EXHIBIT A

FORM OF ASSIGNMENT

THIS DOCUMENT SHALL BE HELD BY AGENT IN ESCROW PURSUANT TO AND IN ACCORDANCE WITH THE PROVISIONS OF THE INTELLECTUAL PROPERTY SECURITY AGREEMENT, DATED AS OF DECEMBER 16, 2011 (AS THE SAME MAY FROM TIME TO TIME BE AMENDED, RESTATED OR OTHERWISE MODIFIED, THE "AGREEMENT"), EXECUTED BY POLYMER TECHNOLOGY SYSTEMS, INC., A CORPORATION ORGANIZED UNDER THE LAWS OF THE STATE OF INDIANA (TOGETHER WITH ITS SUCCESSORS AND ASSIGNS, "PLEDGOR"), IN FAVOR OF PNC BANK, NATIONAL ASSOCIATION, AS AGENT FOR LENDERS, AS DEFINED IN THE AGREEMENT (TOGETHER WITH ITS SUCCESSORS AND ASSIGNS, "AGENT"). BY SIGNING IN THE SPACE PROVIDED BELOW, THE UNDERSIGNED OFFICER OF AGENT CERTIFIES THAT AN EVENT OF DEFAULT (AS DEFINED IN THE AGREEMENT) HAS OCCURRED AND THAT AGENT HAS ELECTED TO TAKE POSSESSION OF THE COLLATERAL ON BEHALF OF AND FOR THE BENEFIT OF LENDERS AND TO RECORD THIS DOCUMENT WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE. UPON RECORDING OF THIS DOCUMENT WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE, THIS LEGEND SHALL CEASE TO HAVE ANY FORCE OR EFFECT.

PNC BANK, NATIONAL ASSOCIATION

By: \_\_\_\_\_  
Print Name: \_\_\_\_\_  
Title: \_\_\_\_\_  
Date: \_\_\_\_\_



ASSIGNMENT

WHEREAS, POLYMER TECHNOLOGY SYSTEMS, INC., a corporation organized under the laws of the State of INDIANA (together with its successors and assigns, "Pledgor"), is the owner of the Collateral, as hereinafter defined;

WHEREAS, Pledgor has executed an Intellectual Property Security Agreement, dated as of even date herewith (as the same may from time to time be amended, restated or otherwise modified, the "Agreement"), in favor of PNC BANK, NATIONAL ASSOCIATION, as Agent for Lenders, as defined in the Agreement (together with its successors and assign in its capacity as agent, "Agent"), pursuant to which Pledgor has granted to Agent, for the benefit of Lenders, a security interest in the Collateral as security for the Debt, as defined in the Agreement;

WHEREAS, the Agreement provides that the security interest in and of the Collateral is effective as of the date of the Agreement;

WHEREAS, the Agreement provides that this Assignment shall become effective upon the occurrence of an Event of Default, as defined in the Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and intending to be legally bound hereby, Pledgor, its successors and assigns, subject to the limitations stated in the paragraph immediately following, does hereby transfer, assign and set over to Agent, its successors, transferees and assigns, all of its existing and future Collateral (as defined in the Agreement), including, but not limited to, the Collateral listed on Schedules A, B, and C of the Agreement (which such schedules shall also be deemed schedules hereto) that is registered in the United States Patent and Trademark Office or that is the subject of pending applications in the United States Patent and Trademark Office.

This Assignment shall be effective only upon the certification of an authorized officer of Agent, as provided above, that (a) an Event of Default, as defined in the Agreement, has occurred, and (b) Agent has elected to take actual title to the Collateral.

IN WITNESS WHEREOF, the undersigned has caused this Assignment to be executed by its duly authorized officer on December \_\_\_\_, 2011.

POLYMER TECHNOLOGY SYSTEMS, INC.

By: \_\_\_\_\_  
Print Name: \_\_\_\_\_  
Title: \_\_\_\_\_

[Signature page – IP Assignment – PTS]

STATE OF \_\_\_\_\_ )  
 ) SS:  
COUNTY OF \_\_\_\_\_ )

BEFORE ME, the undersigned authority, on this day personally appeared \_\_\_\_\_, \_\_\_\_\_, known to me to be the person and officer whose name is subscribed to the foregoing instrument and acknowledged to me that the same was the act of said POLYMER TECHNOLOGY SYSTEMS, INC., an Indiana corporation, and that he/she executed the same as the act of such corporation for the purposes and consideration therein expressed, and in the capacity therein stated.

GIVEN UNDER MY HAND AND SEAL OF OFFICE this \_\_\_\_\_ day of December, 2011.


\_\_\_\_\_  
Notary Public  
My commission expires: \_\_\_\_\_

STATE OF Indiana )  
 ) SS:  
COUNTY OF Marion )

BEFORE ME, the undersigned authority, on this day personally appeared Robert Hottelsoot, President & CEO, known to me to be the person and officer whose name is subscribed to the foregoing instrument and acknowledged to me that the same was the act of said POLYMER TECHNOLOGY SYSTEMS, INC., an Indiana corporation, and that he/she executed the same as the act of such corporation for the purposes and consideration therein expressed, and in the capacity therein stated.

GIVEN UNDER MY HAND AND SEAL OF OFFICE this 13<sup>th</sup> day of December, 2011.

Barney Pearson  
Notary Public  
My commission expires: April 10, 2019



[Notary Page - IP Security Agreement - PTS]